New gastritis drug candidate tested in three formulations to find the best acid controller

NCT ID NCT07717775

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests three different tablet versions of an experimental drug called AD-234 in healthy adults aged 19 to 50. The goal is to see which formulation best controls stomach acid levels over 24 hours after a week of daily dosing. Researchers will also compare how the body absorbs each version and check for side effects. The results will help decide which formulation to study further in people with gastritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug for gastritis, tested in three different formulations called AD-234, AD-2341, and AD-2342
What this could lead to
If successful, this could identify the best formulation of AD-234 for controlling stomach acid, potentially leading to a new treatment option for gastritis.
What could go wrong
This is an early-phase trial in only 30 healthy volunteers, not people with gastritis. The drug may not work as well in actual patients or may have side effects not seen here.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Seoul National University Hospital, Seoul,

    Seoul, South Korea

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.